Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Virtual Reality-Supported Autism Education for Nursing Students (VR-AUTISM-NURS)

12. November 2026 aktualisiert von: Edanur Tar Bolacali, Kirsehir Ahi Evran Universitesi

Effect of a Virtual Reality-Supported Autism Education Program for Nursing Students on Autism-Related Knowledge, Awareness, and Attitudes: A Randomized Controlled Trial

The goal of this clinical trial is to learn if a virtual reality (VR)-supported autism education program improves knowledge, awareness, and attitudes about autism spectrum disorder (ASD) in fourth-year nursing students. The main questions it aims to answer are:

  • Does the program increase nursing students' knowledge of autism?
  • Does the program increase their awareness of autism and improve their attitudes toward people with autism?

Researchers will compare students who take the program with students who receive no education during the study, to see if the program improves knowledge, awareness, and attitudes, and whether these effects last one month after the program.

Participants will:

  • Attend one 90-minute face-to-face session per week for 8 weeks (education group only). Sessions in weeks 1 to 7 use active learning methods such as group work and brainstorming. In week 8, each student watches a short (about 5-minute) 360-degree VR scenario that shows a hospital visit from the point of view of a child with autism, followed by a guided group discussion.
  • Complete questionnaires on autism knowledge, awareness, and attitudes before the program, after the program (week 8), and one month later.

Students in the control group will be offered the same program after the study ends.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Background: Nurses working in primary care and child health services are in a key position to recognize early signs of autism spectrum disorder (ASD) and to refer children for timely assessment. However, nursing students often report limited knowledge and low confidence in this area. Immersive virtual reality (VR) allows learners to experience sensory and social situations from the perspective of a child with autism without involving children in the teaching process.

Design: This is a single-center, two-arm, parallel-group, open-label randomized controlled trial with pretest, posttest, and one-month follow-up measurements. The study will be reported according to CONSORT and the CONSORT-Outcomes 2025 extension.

Randomization: After baseline measurement, participants will be allocated 1:1 by simple randomization using a computer-generated sequence (randomizer.org). Randomization will be performed by an independent researcher not involved in delivering the intervention, and the allocation list will be concealed from the research team until assignment is complete. Data will be coded by group (Group A/Group B) and analyzed by a statistician blinded to group allocation.

Intervention content: Weekly modules cover the diagnostic framework of ASD, social communication and interaction, restricted and repetitive behaviors, sensory experience and perspective taking, comorbidities and differential diagnosis, the nurse's role in early identification and referral, and stigma and professional attitudes. Teaching methods include station rotation, six thinking hats, brainstorming, the six-shoe technique, and cooperative learning (inner-outer circle). Week 8 is a simulation session ("A Journey into the World of a Child with Autism") in which students experience an 8-year-old child's hospital visit first in an unadapted and then in an autism-friendly environment, followed by a structured debriefing. Content will be reviewed by autism experts and piloted with nursing students before the trial.

Statistical analysis: Group-by-time effects across the three measurements will be analyzed with two-way repeated-measures ANOVA, or the nonparametric F1-LD-F1 model if assumptions are not met. Analyses will follow the intention-to-treat principle, and missing data will be handled by multiple imputation. Effect sizes (Cohen's d, partial eta squared) will be reported. The significance level is p<0.05.

Studientyp

Interventionell

Einschreibung (Geschätzt)

80

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Fourth-year student in the Department of Nursing, Faculty of Health Sciences, Kirsehir Ahi Evran University
  • Has completed the pediatric (child health and diseases) nursing course
  • Has not previously attended a structured education program on autism spectrum disorder
  • Agrees to participate voluntarily and signs the informed consent form
  • Is able to attend the education sessions and measurements

Exclusion Criteria:

  • Known health condition that may prevent the use of virtual reality (e.g., severe motion sickness or vertigo, epilepsy)
  • Not completing the baseline (pretest) measurements

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Sonstiges
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: VR-Supported Autism Education

Participants will attend an 8-week modular autism education program with one 90-minute face-to-face session per week. Weeks 1-7 consist of active learning modules on autism spectrum disorder. Week 8 consists of a virtual reality simulation session followed by a structured debriefing.

An 8-week program with one 90-minute face-to-face session per week. Weeks 1-7 cover the diagnostic framework of autism spectrum disorder, social communication and interaction, restricted and repetitive behaviors, sensory experience and perspective taking, comorbidities and differential diagnosis, the nurse's role in early identification and referral, and stigma and professional attitudes, using station rotation, six thinking hats, brainstorming, six-shoe technique, and cooperative learning methods. In week 8, each student experiences an approximately 5-minute immersive 360-degree VR scenario of an 8-year-old child's hospital visit from the child's perspective, first in an unadapted and then in an autism-friendly environment, followed by a structured debriefing.

Kein Eingriff: Control

Participants will receive no education during the study period and will complete the same questionnaires at the same time points (baseline, week 8, and week 12). They will be offered the same education program after the follow-up measurement.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Autism Knowledge Score (Knowledge about Childhood Autism among Health Workers Questionnaire)
Zeitfenster: Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Autism knowledge will be measured with the Turkish version of the Knowledge about Childhood Autism among Health Workers (KCAHW) Questionnaire. It has 19 items covering social interaction, communication, behavioral patterns, and features of the disorder. Each correct answer scores 1 and each incorrect or "don't know" answer scores 0, giving a total score of 0 to 19. Higher scores indicate greater knowledge of childhood autism.

Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Autism Awareness Score (Autism Awareness Scale)
Zeitfenster: Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Autism awareness will be measured with the Autism Awareness Scale, which has 32 items in 7 subscales (restricted interests and repetitive behaviors, social interaction and communication, causes of autism, peer relationships, key elements of intervention, physical characteristics, and early warning signs). Items are rated on a 5-point Likert scale (1 = strongly disagree, 5 = strongly agree), with reverse-scored items, giving a total score of 32 to 160. Higher scores indicate greater awareness of autism.

Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)
Attitudes Toward Autism Score (Societal Attitudes Towards Autism Scale)
Zeitfenster: Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Attitudes toward autism will be measured with the Turkish version of the Societal Attitudes Towards Autism (SATA) Scale, which has 26 items in 3 subscales (personal distance, knowledge, and social life). Items are rated on a 4-point scale, with reverse-scored items, giving a total score of 26 to 104. Higher scores indicate more positive attitudes toward individuals with autism.

Baseline (before the intervention), week 8 (immediately after the intervention), and week 12 (one month after the intervention)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

17. November 2026

Primärer Abschluss (Geschätzt)

15. Januar 2027

Studienabschluss (Geschätzt)

28. Februar 2027

Studienanmeldedaten

Zuerst eingereicht

12. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. November 2026

Zuerst gepostet (Tatsächlich)

18. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

12. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • SYO.A3.26.005

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual participant data will not be shared publicly because participants were informed in the consent process that their data would be used only by the research team for scientific purposes. Aggregate results will be published in a peer-reviewed journal. De-identified data may be made available by the principal investigator upon reasonable request after publication, subject to ethics committee approval.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .